Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class ASSE: 603707

Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Idarubicin Hydrochloride Injection from FDA of the United States

· Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Idarubicin Hydrochloride Injection from FDA of the United States

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis